The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness
Open accessAbstract
Fluoroquinolones are antibacterial drugs that inhibit DNA Gyrase and Topoisomerase IV. These essential enzymes facilitate chromosome replication and RNA transcription by regulating chromosome supercoiling. High-level resistance to fluoroquinolones in E. coli requires the accumulation of multiple mutations, including those that alter target genes and genes regulating drug efflux. Previous studies have shown some drug-resistance mutations reduce bacterial fitness, leading to the selection of fitness-compensatory mutations. The impact of fluoroquinolone-resistance on bacterial fitness was analyzed in constructed isogenic strains carrying up to 5 resistance mutations. Some mutations significantly decreased bacterial fitness both in vitro and in vivo. We identified low-fitness triple-mutants where the acquisition of a fourth resistance mutation significantly increased fitness in vitro and in vivo while at the same time dramatically decreasing drug susceptibility. The largest effect occurred with the addition of a parC mutation (Topoisomerase IV) to a low-fitness strain carrying resistance mutations in gyrA (DNA Gyrase) and marR (drug efflux regulation). Increased fitness was accompanied by a significant change in the level of gyrA promoter activity as measured in an assay of DNA supercoiling. In selection and competition experiments made in the absence of drug, parC mutants that improved fitness and reduced susceptibility were selected. These data suggest that natural selection for improved growth in bacteria with low-level resistance to fluoroquinolones could in some cases select for further reductions in drug susceptibility. Thus, increased resistance to fluoroquinolones could be selected even in the absence of further exposure to the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genetical theory of natural selection
Fisher, R. A. (1930) · doi:10.5962/bhl.title.27468 · Cited by 17,617
Escherichia coli and Salmonella :cellular and molecular biology
Neidhardt, F. C. (1996) · ASM Press eBooks · Cited by 8,197
Cherepanov, P. P., & Wackernagel, W. (1995) · Gene · doi:10.1016/0378-1119(95)00193-a · Cited by 1,937
An efficient recombination system for chromosome engineering in Escherichia coli
Yu, D., Ellis, H. M., Lee, E.-C., Jenkins, N. A., Copeland, N. G., & Court, D. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100127597 · Cited by 1,688
Darwinian Evolution Can Follow Only Very Few Mutational Paths to Fitter Proteins
Weinreich, D. M., Delaney, N. F., DePristo, M. A., & Hartl, D. L. (2006) · Science · doi:10.1126/science.1123539 · Cited by 1,415
Modulation of Chemical Composition and Other Parameters of the Cell by Growth Rate
Bremer, H. J. (1999) · Cited by 915
The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627
Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones
Hooper, D. C. (2001) · Clinical Infectious Diseases · doi:10.1086/319370 · Cited by 517
The biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
The Quinolones: Past, Present, and Future
Andriole, V. T. (2005) · Clinical Infectious Diseases · doi:10.1086/428051 · Cited by 428
Regulation of bacterial drug export systems
Grkovic, S., Brown, M. H., & Skurray, R. A. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.4.671-701.2002 · Cited by 423
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397
Komp Lindgren, P., Karlsson, A., & Hughes, D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3222-3232.2003 · Cited by 350
Self-citationBagel, S., Hüllen, V., Wiedemann, B., & Heisig, P. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.868 · Cited by 217
Borman, A. M., Paulous, S., & Clavel, F. (1996) · Journal of General Virology · doi:10.1099/0022-1317-77-3-419 · Cited by 155
Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae
Rozen, D. E., McGee, L., Levin, B. R., & Klugman, K. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01161-06 · Cited by 151
Hvidberg, H., Struve, C., Krogfelt, K. A., Christensen, N., Rasmussen, S. N., & Frimodt‐Møller, N. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.156-163.2000 · Cited by 150
Self-citationO’Neill, A. J., Huovinen, T., Fishwick, C. W. G., & Chopra, I. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.298-309.2006 · Cited by 143
European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe
Ferech, M., Coenen, S., Malhotra‐Kumar, S., Dvorakova, K., Hendrickx, E., Suetens, C., & Goossens, H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl183 · Cited by 111
Topoisomerase IV, alone, unknots DNA in E. coliPreprint
Deibler, R. W., Rahmati, S., & Zechiedrich, L. (2001) · Genes & Development · doi:10.1101/gad.872301 · Cited by 110
Evolutionary Biology of Bacterial and Fungal Pathogens
Hinchliffe, S., Strong, P., Sl, H., & Wren, B. W. (2007) · ASM Press eBooks · doi:10.1128/9781555815639 · Cited by 96
A unified anti-mutant dosing strategy
Zhao, X., & Drlica, K. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn229 · Cited by 75
Fitness effects of amino acid replacements in the beta-galactosidase of Escherichia coli.
Dean, A. M., Dykhuizen, D. E., & Hartl, D. L. (1988) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a040513 · Cited by 29
Preisler, A., Mraheil, M. A., & Heisig, P. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki475 · Cited by 19
The units of selection and measures of fitness
Demetrius, L. (1985) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1985.0056 · Cited by 12
Cited by
Understanding the mechanisms and drivers of antimicrobial resistance
Holmes, A. H., Moore, L. S. P., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P. J., & Piddock, L. J. V. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00473-0 · Cited by 2,611
Antibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294
Self-citationSelection of Resistant Bacteria at Very Low Antibiotic Concentrations
Gullberg, E., Cao, S., Berg, O. G., Ilbäck, C., Sandegren, L., Hughes, D., & Andersson, D. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002158 · Cited by 1,654
Self-citationBeceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,070
Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.007 · Cited by 1,008
Metadata
- Authors
- Marcusson, L. L., Frimodt-Møller, N., & Hughes, D.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-08-07
- Volume
- 5
- Issue
- 8
- Pages
- e1000541
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2043887558
- Cited by
- 320
- References
- 25
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.